Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 3/20 | 0.36 |
| ▸ | ADH1C | P00326 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27010027 | 1.00 | CYP1A2 (0.39) | CYP1A2ADH1AADH1CALOX5SIGMAR1 | |
| SCHEMBL24316189 | 1.00 | CYP1A2 (0.39) | CYP1A2ADH1AADH1CALOX5SIGMAR1 | |
| SCHEMBL27010026 | 0.98 | CYP1A2 (0.35) | CYP1A2ADH1AADH1CALOX5SIGMAR1 | |
| SCHEMBL27010025 | 0.94 | ADH1A (0.34) | CYP1A2ADH1AADH1CALOX5 | |
| SCHEMBL1911476 | 0.90 | ALDH1A1 (0.34) | — | |
| SCHEMBL24316183 | 0.85 | — | — | |
| SCHEMBL27010032 | 0.85 | PIK3CD (0.30) | — | |
| SCHEMBL24316180 | 0.85 | CNR2 (0.31) | RORC | |
| SCHEMBL27010035 | 0.85 | — | — | |
| SCHEMBL27010037 | 0.84 | CYP1A2 (0.31) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CYP1A2 2070/4885ADH1A 3222/4885ADH1C 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.